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Abstract
Purpose: This phase II neoadjuvant study investigated whether nab-paclitaxel, carboplatin and bevacizumab given before 
neoadjuvant doxorubicin/cyclophosphamide (AC) produced higher pathologic complete response (pCR) rates in triple-
negative breast cancer (TNBC) compared with historical results achieved with standard anthracycline/taxane regimens.
Patients and Methods: Eligible patients with operable TNBC ≥2 cm received four cycles of carboplatin (area under 
the curve 6, day 1) plus nab-paclitaxel (100 mg/m2, days 1, 8 and 15) every 28 days, followed by four 14-day cycles 
of AC neoadjuvantly, with bevacizumab 10 mg/kg every 14 days for the first 6 cycles of neoadjuvant chemotherapy, 
resuming postoperatively to complete 1 year of antibody treatment. In-breast pCR and pCR (breast + nodes) were 
primary and secondary endpoints, respectively.
Results: Due to slow accrual, the study was closed after enrollment of 42 of 60 planned patients. Of the 38 patients 
who underwent surgery (efficacy population), 22 (58%) achieved an in-breast pCR and 19 (50%) achieved a pCR 
(breast + nodes). Neutropenia was the most common Grade 3/4 adverse event (57% Grade 3 and 31% Grade 4), 
but only 1 patient required hospitalisation and IV antibiotics for neutropenic fever. Other Grade 3/4 events included 
anaemia (24%), thrombocytopenia (29%) and peripheral neuropathy (Grade 3, 5%).
Conclusion: Our results demonstrate a substantially higher pCR rate, both in-breast and breast + nodes, with the 
combination of nab-paclitaxel plus carboplatin followed by AC, with concurrent bevacizumab, versus historic 
pCR rates with anthracycline-taxane regimens alone, supporting further investigation of this regimen, preferably in 
molecularly driven subsets, for the neoadjuvant treatment of patients with TNBC.
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Introduction
Triple-negative breast cancer (TNBC) is generally more 
chemosensitive, with higher pathologic complete response 
(pCR) rates after neoadjuvant therapy compared with 
other subtypes of breast cancer.[1,2] Patients with TNBC 
who achieve a pCR have survival outcomes similar to the 
other breast cancer subtypes but a greater risk of relapse 
if residual disease remains.[2] pCR has been shown to 
correlate with improved disease-free survival (DFS) 
and overall survival (OS) in breast cancer.[3,4] However, 
with standard anthracycline plus taxane regimens, only 
about 20–25% of hormone receptor-negative breast 
cancer patients achieve a pCR.[3,5] Furtheroptimisation of 
neoadjuvant treatment for TNBC is needed.
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In patients with metastatic breast cancer (MBC), every 
3-week nab-paclitaxel was superior to solvent-based 
paclitaxel.[6] Basal-like breast cancers overexpress secreted 
protein acidic and rich in cysteine (SPARC).[7] In pre-clinical 
models, SPARC transports albumin-bound (nab-) paclitaxel 
intracellularly, through SPARC-GP60-Caveolin 1 binding, 
that may contribute to antitumour efficacy.[8] A higher 
frequency of BRCA-1 deficiency and other DNA damage 
repair defects in sporadic basal-like breast cancer may 
make these tumours more sensitive to platinum drugs.[9,10] 
Carboplatin plus solvent-based paclitaxel was evaluated in 
first-line MBC, with higher response rates (RRs) compared 
to single-agent paclitaxel.[11,12] A phase I trial demonstrated 
the feasibility of combining nab-paclitaxel with carboplatin 
in solid tumours, including MBC.[13] Angiogenesis also plays 
an integral role in the growth and progression of breast cancer. 
In the E2100 trial, bevacizumab added to weekly paclitaxel 
significantly improved RRs and median progression-free 
survival in HER2-negative MBC.[14]
Based on this efficacy data in the metastatic setting, we 
designed the current trial to evaluate whether integrating 
nab-paclitaxel, carboplatin and bevacizumab into an 
anthracycline-based neoadjuvant regimen would increase 
pCR rates with an acceptable safety and tolerability profile 
in patients with operable TNBC.
Patients and Methods
Patient eligibility
Eligible patients were women ≥18 years of age with 
palpable (≥2 cm) and operable, histologically confirmed, 
oestrogen receptor (ER) and progesterone receptor-
negative (per local testing, eligibility confirmed centrally 
by review of pathology reports), and negative for HER2 (0 
or 1+ on immunohistochemistry and/or documented 
non-amplification by fluorescence in situ hybridisation) 
invasive ductal carcinoma of the breast, with or without 
clinically positive nodes. Clinically positive nodes were 
identified by physical examination or imaging. Pathologic 
confirmation of clinically positive nodes such as with fine 
needle aspiration was not required but allowed. Eastern 
Cooperative Oncology Group (ECOG) performance status 
of 0–1, baseline cardiac ejection fraction (EF) ≥lower limit 
of normal (LLN) and adequate haematologic, renal and 
hepatic function were also required. Sentinel node biopsy 
before treatment was discouraged but not prohibited.
Major exclusion criteria included metastatic, T4, clinical 
N2b or N3 or inflammatory breast cancer; significant 
cardiac disease, uncontrolled hypertension, thrombotic 
or haemorrhagic events, coagulation disorders, another 
primary malignancy except treated basal or squamous 
cell carcinoma of the skin or in situ cervical cancer, unless 
disease-free for ≥5 years. All patients provided written 
informed consent, and the study was approved by the 
institutional review board at each site.
Study design and treatment
This was a phase II, open-label, single arm non-
randomised study. All patients were required to undergo 
pre-treatment breast biopsies for correlative analyses. 
Whole blood and plasma samples were also collected at 
pre-specified time points. Patients received four 28-day 
cycles of intravenous nab-paclitaxel (100 mg/m2 on days 
1, 8 and 15 over 30 min) plus carboplatin (area under the 
curve [AUC] 6 on day 1 over 30 min), plus bevacizumab 
(10 mg/kg on days 1 and 15; over 90 min for cycle 1, 
over 60 and 30 min for cycle 2 and beyond, respectively) 
[Figure 1].
This was followed by four 14-day cycles of intravenous 
doxorubicin/cyclophosphamide (AC) (doxorubicin 
[60 mg/m2 on day 1 over 15 min], cyclophosphamide 
[600 mg/m2 on day 1 over 30 min]) and bevacizumab 
(10 mg/kg on day 1 for the first 2 cycles only). Surgery, 
including axillary staging, was performed between 2 and 
6 weeks after the last dose of AC. Postoperatively, patients 
received eight 28-day cycles of bevacizumab (10 mg/kg on 
days 1 and 15) after a minimum of 4 weeks from surgery 
and evidence of complete wound healing.
During pre-operative cycles 5–8, prophylactic granulocyte 
colony-stimulating factor (G-CSF) was required. During 
cycles 1–4, G-CSF was not to be used as primary 
prophylaxis but was allowed for febrile neutropenia and 
as secondary prophylaxis for subsequent cycles.
Dose modification criteria for haematologic and non-
haematologic toxicities are described in Supplementary 
Appendix 1. Mid-study, in compliance with the FDA 
guidance issued around changes in creatinine methodology 
and carboplatin dosing, a glomerular filtration rate cap of 
125 mL/min was implemented for the Calvert formula so 
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that the maximum dose of carboplatin for any patient was 
not to exceed 900 mg.[15]
No dose reductions of bevacizumab were allowed, and 
treatment was held if the chemotherapy component was 
delayed. Protocol-specified therapy was discontinued for 
progressive disease, unacceptable toxicity, withdrawal of 
consent or physician judgment.
Efficacy and safety assessments
The primary endpoint of the study was the in-breast pCR 
rate after 8 cycles of pre-operative therapy, defined as 
no histologic evidence of invasive tumour cells (with or 
without carcinoma in situ) in the surgical breast specimen. 
Secondary objectives included near-pCR rate (≤0.5 cm of 
residual invasive tumour in the breast) and pCR breast 
+ nodes (no invasive tumour cells in the breast, axillary 
and sentinel nodes). Clinical response was assessed by 
physical examination, with clinical complete response 
(cCR), clinical partial response (cPR) and stable disease 
(SD) defined by Response Evaluation Criteria in Solid 
Tumours version 1.0 (Supplementary Appendix 2). Rate of 
breast-conserving surgery, safety and tolerability were also 
assessed, including cardiac safety with echocardiogram 
or multigated acquisition (MUGA) scans required on 
all patients at pre-specified time points. Toxicities were 
graded using the NCI common terminology criteria of 
adverse events (AEs) version 3.0.
Statistical considerations
A 60 patient sample size, assuming a 10% attrition rate, 
was calculated based on an estimated pCR rate of 25% 
with a standard taxane plus anthracycline regimen in ER-
negative and HER2-negative tumours in earlier studies. 
A sample size of 57 patients would be required to show 
an increase in pCR rate to 40%, to test this one-sided 
hypothesis with approximately 80% power and a type I 
error rate (alpha) ≤0.05. The efficacy population was 
defined as all patients who underwent definitive breast 
surgery and was used for the efficacy analyses of cRR and 
Figure 1: Treatment schema
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pCR. The evaluable population was defined as all patients 
who received at least 75% of the total protocol defined 
pre-operative treatment cycles and for whom pathological 
response data were available. The safety population 
included all patients who received at least 1 dose of study 
treatment. Statistical analyses were descriptive.
Results
Patient characteristics
Forty-two of 60 planned patients were enrolled between 
January 2009 and January 2013 and received treatment 
on the study. At the prevailing accrual rate, it would 
have required an additional 12-18 months to enroll 
the remaining evaluable patients provided no other 
competing studies were to open during the same time 
period, so accrual was closed at that point. Baseline 
characteristics are described in Table 1. 38 patients 
proceeded to surgery and constitute the efficacy 
population, 4 patients came off the study before surgery 
(2 for patient decision, 1 for disease progression and 1 
for atypical chest pain); 36 patients received ≥75% of the 
required pre-operative therapy (≥6 cycles) and comprise 
the evaluable population. The post-operative portion 
of the study is still ongoing, and the present analysis is 
restricted to the reporting of the primary endpoint of pCR 
after pre-operative treatment.
Treatment delivery
Among the 38 patients who constitute the efficacy 
population, 29 patients (76%) missed at least one dose of 
nab-paclitaxel of a total of 12 planned doses over 4 cycles. 
The median dose intensity/week of nab-paclitaxel 
averaged over 4 cycles was 68.75 mg/m2 (37.5–75 mg/m2), 
which was 92% of the planned dose intensity/week/
cycle (75 mg/m+). The median dose intensity delivered 
for the other agents was 100% of planned. Two patients 
required a dose reduction of nab-paclitaxel to dose 
level-1 (80 mg/m2), and four patients required reduction 
of carboplatin to dose level-1 (AUC 5) for haematologic 
toxicity. Two patients did not complete at least 75% of 
the planned cycles before proceeding to surgery due to 
haematologic toxicities.
Treatment response
In the efficacy population, an in-breast pCR (primary 
endpoint) was observed in 22 patients (58%; 95% 
confided interval [CI]: 41–74%); 19 patients (50%; 
95% CI: 33–67%) experienced pCR in both breast and 
nodes. An additional three patients (8%) experienced a 
near-pCR inthe breast, while residual tumour >0.5 cm 
was found in 13 patients (34%). Similar results were 
observed in the evaluable population [Table 2]. Of the 
23 patients who were clinically node positive at baseline, 
20 were evaluable for the pCR endpoint. Twelve of these 
20 patients (60%) achieved a pN0 status (pathologically 
negative nodes) at surgery. An additional three patients 
had micrometastatic disease in the nodes (pN1mi).
A cCR was observed in 29 of 38 patients (76%) in the 
efficacy population, 5 (13%) achieved a cPR and 3 (8%) 
had SD [Table 2]. RRs were similar in the evaluable 
population.
Table 1: Baseline patient demographics and clinical 
characteristics
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Toxicity
The majority of AEs were Grade 1/2 (57% Grade 1, 
29% Grade 2, 12% Grade 3 and 2% Grade 4). Ten of 
42 patients (24%) experienced at least 1 serious adverse 
event (SAE) related to study treatment, with a total of 23 
SAEs [Supplemental Table 1].
The most frequent AEs (all grades) were anaemia (81%), 
neutropenia (81%), nausea (76%), fatigue (71%) and 
thrombocytopenia (60%) [Table 3]. The most frequent 
Grade 3/4 AEs were neutropenia (57% Grade 3 and 31% 
Grade 4), thrombocytopenia (29% Grade 3) and anaemia 
(21% Grade 3 and 2% Grade 4). Despite the high rate 
of neutropenia, only one patient developed neutropenic 
fever requiring IV antibiotics. Peripheral neuropathy was 
reported in 31% of patients (5% Grade 3). Grade 1/2 
hypertension and proteinuria occurred in 36% and 10% 
of patients, respectively, and there were no reported 
Grade 3/4 events.
Cardiac function was assessed at baseline and before 
surgery. Of the 42 patients, paired echocardiograms or 
MUGA scans were available for 37. The median EF 
at baseline was 62.4% (range 53.0–80.0), compared 
with 60.2% (range 48.7–70.7) at the completion of pre-
operative treatment. Six patients experienced a drop in 
EF ≥10% but not to below the institutional LLN. There 
were no cases of clinical congestive heart failure reported.
Discussion
To our knowledge, this is the first report of a combination 
of weekly nab-paclitaxel plus carboplatin followed by AC 
with concurrent bevacizumab in the neoadjuvant treatment 
of TNBC. In this study, we observed a 58% in-breast pCR 
rate and 50% of patients achieved a pCR in both breast 
and nodes.
To put our results in context, we examined recently 
presented data from two randomised phase II trials 
evaluating similar neoadjuvant regimens for early-stage 
breast cancer. [Table 4] In the GeparSixto trial, a significant 
increase in the pCR rate (breast plus nodes), from 36.9% 
to 53.2% (p = 0.005), was observed with the addition of 
carboplatin for patients with TNBC. All patients received 
bevacizumab.[16] Similarly, the Cancer and Leukaemia 
Group (CALGB) 40603 trial in a 2 × 2 randomised design 
reported an absolute difference of 14% in breast pCR rate 
with carboplatin versus no carboplatin (60% vs. 46%, 
P = 0.0018), and 11% (59% vs. 48%, P = 0.0089) with 
bevacizumab versus no bevacizumab.[17] No significant 
Table 2: Patient RRs and surgical outcomes





In‑breast pCR 22 (58) 21 (58)
pCR breast+nodes 19 (50) 18 (50)
pCR (breast only) 3 (8) 3 (8)
Near‑pCR breast (Residual tumour≤0.5 cm in breast) 3 (8) 2 (6)
Residual disease (tumour >0.5 cm in breast) 13 (34) 13 (36)
Best clinical response
CR 29 (76) 28 (78)
PR 5 (13) 4 (11)
SD 3 (8) 3 (8)
Missinga 1 (3) 1 (3)
Surgical outcome
Breast‑conserving surgery 20 (53) 19 (53)
Mastectomy 18 (47) 17 (47)
aClinical response could not be verified, RRs: Response rates. pCR: Pathologic complete response, CR: Complete response, PR: Partial re‑
sponse, SD: Stable disease
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treatment interaction was found between carboplatin 
and bevacizumab (P = 0.52). Intrinsic subtyping based 
on PAM50 showed an association between higher pCR 
rates in the basal subtype of TNBC for bevacizumab, 
but a similar predictive value was not demonstrated for 
carboplatin. No definite mRNA gene expression signatures 
predictive for carboplatin benefit were revealed.[18]
The lack of a control arm in our study, the presence of 
bevacizumab in both arms in the GeparSixto trial, and 
the lack of power to compare the carboplatin arm alone 
to the control arm without carboplatin or bevacizumab in 
the CALGB 40603 trial make it difficult to definitively 
conclude the contribution of carboplatin to pCR rates. 
However, these trials including our study provide a 
consistent signal of similar significant increases in pCR 
rates with carboplatin added to a taxane plus anthracycline 
backbone in TNBC. In addition, in the ISPY-2 trial, the 
combination of carboplatin plus veliparib plus standard 
neoadjuvant chemotherapy predicted for a pCR rate of 
52% in the hormone receptor-negative/HER2-negative 
subgroup compared with 26% in the control group based 
Table 3: AEs occurring in >5% of patients (n=42)
Adverse Event Any grade n (%) Grade 3 n (%) Grade 4 n (%)
Haematologic
Anaemia 34 (81) 9 (21) 1 (2)
Neutropenia 34 (81) 24 (57) 13 (31)
Thrombocytopenia 25 (60) 12 (29) 0
Non‑haematologic
Nausea 32 (76) 2 (5) 0
Fatigue 30 (71) 2 (5) 0
Mucositis 21 (50) 2 (5) 0
Alopecia 16 (38) 1 (2) 0
Epistaxis 16 (38) 0 0
Anorexia 15 (36) 1 (2) 0
Hypertension 15 (36) 0 0
Peripheral neuropathy 13 (31) 2 (5%) 0
Diarrhoea 10 (24) 0 0
Vomiting 10 (24) 2 (5) 0
Taste alteration 9 (21) 0 0
Dyspnoea 8 (19) 0 0
Constipation 7 (17) 0 0
Headache 7 (17) 1 (2) 0
LFT elevation 7 (17) 0 0
Pain 7 (17) 0 0
Bone pain 6 (14) 1 (2) 0
Urinary tract infection 5 (12) 1 (2) 0
Dyspepsia 4 (10) 0 0
Proteinuria 4 (10) 0 0
Cough 3 (7) 0 0
Dehydration 3 (7) 1 (2) 0
Flu‑like syndrome 3 (7) 0 0
GERD 3 (7) 0 0
Hot flashes 3 (7) 1 (2) 0
Hypokalaemia 3 (7) 0 0
AEs: Adverse events
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on a Bayesian prediction model.[18] A large phase 3 
randomised study is evaluating this combination in TNBC 
(clinicaltrials.gov NCT02032277).
The first randomised comparison of nab-paclitaxel versus 
solvent-based (sb)-paclitaxel in the neoadjuvant setting 
was presented recently. Results from the randomised 
GeparSepto trial demonstrated a superior pCR rate 
(breast plus nodes) with nab-paclitaxel versus weekly 
sb-paclitaxel in the context of a standard anthracycline/
taxane neoadjuvant regimen (38% vs. 29%; P = 0.001), 
although the rate of Grade 3/4 peripheral neuropathy was 
also increased.[19] Notably, the subset of patients with 
TNBC appeared to derive the greatest benefit from nab-
paclitaxel in this study (odds ratio 2.69, pCR rates 48% 
vs. 29% P < 0.001). It is likely that, within TNBC, certain 
molecular subsets (e.g. the mesenchymal or mesenchymal 
stem cell-like)[20] with high expression of genes encoding 
for epithelial-mesenchymal transition (e.g. SPARC) could 
potentially be more sensitive to nab-paclitaxel compared 
to sb-paclitaxel. Correlative analyses to be conducted in 
the near future on the pre-operative biopsy samples from 
our study and studies like the GeparSepto trial may lend 
some useful insight into this.
Bevacizumab has been evaluated for neoadjuvant breast 
cancer treatment in randomised trials that included 
subsets of TNBC patients [Table 4]. Although small 
increases in pCR rates were observed in the National 
Surgical Adjuvant Breast and Bowel Project B-40 and 
GeparQuinto trials with the addition of bevacizumab 
to chemotherapy, the benefit in the TNBC subset was 
not consistent [Table 4].[21,22] Correlative data from the 
CALGB 40603 study do lend a worthwhile hypothesis 
Table 4: Summary of recent randomised neoadjuvant trials investigating carboplatin and/or bevacizumab in 
TNBC[16,17,21,22]












pCR (breast+nodes): 18.4% (with beva‑
cizumab) versus 14.9% (no bevacizumab) 
(P=0.04)
TNBC subset: 39.3% (with bevacizumab) 
versus 27.9% (no bevacizumab)  
(P=0.003)








ondary randomisation to 
bevacizumab
In‑breast pCR: Evaluable patients 
34.5% (with bevacizumab) versus 
28.2% (chemotherapy alone) (P=0.02)
HR‑negative (TNBC) Subset
51.5% (with bevacizumab) versus 





TNBC (n=443) 2×2 Randomisation: Weekly 
Paclitaxel → ddAC±Carboplat‑
in±Bevacizumab
In‑breast pCR: 60% (with carboplatin) 
vs. 46% (no carboplatin) (P=.0018) 
59% (with bevacizumab) vs. 48% (with‑
out bevacizumab) (P=.0089)
pCR (breast+nodes): 54% (with 
carboplatin) versus 41% (no carbopla‑
tin) (P=0.0029) 52% (with bevacizumab) 





TNBC (n=315) Weekly Paclitaxel/PLD/beva‑
cizumab±Carboplatin
pCR (breast+nodes): 53.2% (carbo‑
platin) versus 36.9% (no carbopla‑
tin) (P=0.005)
HR: Hormone receptor, TNBC: Triple‑negative breast cancer, EC: Epirubicin/cyclophosphamide, Pcr: Pathologic complete response, NS‑
ABP: National Surgical Adjuvant Breast and Bowel Project, AC: Doxorubicin/cyclophosphamide, CALGB: Cancer and leukaemia group B, 
ddAC: Dose‑dense doxorubicin/cyclophosphamide, PLD: Pegylated liposomal doxorubicin
JOURNAL OF CANCER & ALLIED SPECIALTIES 8
ORIGINAL ARTICLE J Cancer Allied Spec 2016;2(1):3
for a basal-like intrinsic subtype, higher expression of a 
proliferation signature and lower expression of oestrogen 
signature as being predictive of increased pCR rates 
with bevacizumab. These will require further large-scale 
validation before being considered for stratification of 
patients for treatment decisions.[18]
In our trial, patients also received an additional eight cycles 
of bevacizumab after completion of surgery. Results of this 
phase are not yet mature and will be reported in the future. 
However, 1 year of adjuvant bevacizumab plus chemotherapy 
for patients with TNBC in the phase III BEATRICE trial 
produced no improvement in invasive DFS or OS compared 
to chemotherapy alone.[23] Similarly, the recently presented 
ECOG 5103 adjuvant trial in HER2-negative breast cancer 
did not show a DFS advantage for 6 or 12 months of post-
operative bevacizumab added to chemotherapy versus 
chemotherapy alone.[24] These data together do not support 
a significant role of bevacizumab in the treatment of early-
stage TNBC at this point in time. Correlative biomarkers 
from these large adjuvant studies might identify potential 
subgroups of patients likely to derive benefit.
With regard to tolerability, the majority of AEs in our study 
were Grade 1/2, with a 14% rate of Grade 3 or 4 events. 
Despite the high rate of Grade 3/4 neutropenia, the rate of 
febrile neutropenia was very low, likely due to the frequent 
use of G-CSF after cycle 1. The rates of neutropenia are 
consistent with other trials combining both carboplatin and 
bevacizumab with standard neoadjuvant chemotherapy. 
Also consistent among the different trials is the 
observation that the addition of carboplatin with or without 
bevacizumab interferes with the delivery of all 12 planned 
weekly doses of the taxane. In our study and in CALGB 
40603,[17] approximately 60-65% of the patients received 
11–12 planned doses of the taxane when both carboplatin 
and bevacizumab were also administered. In the GeparSixto 
trial, the mean relative total dose intensity (RTDI) of all 
treatments in the TNBC cohort was 80% without and 71% 
with carboplatin (P < 0.0001).[16] The mean RTDI increased 
from 68% to 72% when the dose of carboplatin was reduced 
from an AUC of 2 to AUC 1.5, accompanied by a lower 
rate of treatment discontinuation.[16]
This study along with the other recent neoadjuvant studies 
discussed above underscores the heterogeneity of the 
TNBC population, and not all patients benefit from the 
addition of platinum agents and other targeted therapies. 
The additional toxicity and the compromised delivery of 
the standard backbone drugs need to be kept in mind when 
advocating for more intensified neoadjuvant regimens 
for all patients with TNBC. Future studies should focus 
on evaluating distinct molecular subsets with differing 
sensitivity to cytotoxic and biologic agents.[20,25] For 
instance, an analysis of homologous recombination 
deficiency (HRD) in breast cancer identified one-third of 
TNBCs (36%) that could potentially benefit from DNA 
damaging drugs like[26,27] the platinum compounds alone 
or in combination with poly (ADP ribose) polymerase 
(PARP) inhibitors based on HRD.[26] The PrECOG 
study 0105 evaluated the combination of carboplatin 
plus gemcitabine plus iniparib neoadjuvantly in TNBC 
patients with or without germline BRCA mutations.[27] 
A higher pCR rate was observed for tumours with a 
higher HRD score irrespective of germline BRCA status. 
Subclassification of responders and non-responders into 
molecular subsets showed the highest responses in the 
immunomodulatory subset and no responses in the luminal 
androgen receptor-like subset. Recent data from the 
GeparSixto trial correlated a higher expression of immune-
related genes and tumour-infiltrating lymphocytes with 
higher pCR rates.[28] The development of multiple T-cell 
checkpoint inhibitors might offer an opportunity to 
further enhance response to neoadjuvant chemotherapy 
for patients in the near future.
Finally, in a recently published pooled analysis of 
12 neoadjuvant breast cancer studies, the prognostic 
correlation of pCR with event-free survival (EFS) and 
OS was shown for TNBC and HER2-positive breast 
cancer treated with trastuzumab.[29] Alhough the individual 
trial level data failed to show a correlation between the 
treatment effect on pCR and EFS or OS, the authors 
concluded that the heterogeneous study populations 
and the small absolute difference in pCR rates between 
the treatment and control arms in the majority of these 
trials were unlikely to be sufficient to impact a change in 
EFS and OS. More effective therapies in homogeneous 
subsets of breast cancer that produce larger absolute 
differences in pCR rates, as reported by our group and 
other contemporary trials, could be speculated to produce 
a meaningful treatment effect on EFS and OS when 
analysed in the future.
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Conclusion
Our study has demonstrated substantially higher pCR rates 
with the combination of nab-paclitaxel plus carboplatin 
followed by AC, with concurrent bevacizumab, compared 
with historic rates associated with anthracycline-taxane 
regimens alone. Correlative data from this study and the 
other recent studies exploring similar combinations will 
hopefully allow selection of certain subsets of TNBC 
patients for whom further investigation of this regimen 
would be warranted. Longer follow-up of our study and 
others is needed to establish the impact of these novel 
regimens on survival outcomes in TNBC.
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Supplemental Table 1: Serious adverse events 
occurring during the pre-operative phase
Symptoms n (%)
Anaemia 1 (4)
Cardiac troponin T elevation 1 (4)
Chest pressure 1 (4)
Dehydration 2 (9)
Epistaxis 2 (9)
Failure to thrive 1 (4)
Fever 1 (4))








Supplementary Appendix 1: Dosage and Schedule 
Modifications for Haematologic and Non-Haemato-
logic Toxicities
Carboplatin and/or nab-paclitaxel were delayed and/or 
reduced for absolute neutrophil counts (ANC) of <1500 μL, 
or platelet counts <100,000 lasting ≤3 weeks; withdrawal 
from the study was required if ANC or platelets had not 
recovered within 3 weeks. nab-Paclitaxel was delayed and/
or dose reduced for Grade 2/3 peripheral neuropathy, and 
drug was discontinued for Grade 4 events, Grade 3 events 
persisting >7 days, or for the third episode of Grade 3 
neuropathy of 1–7 days duration. Carboplatin and/or nab-
paclitaxel were discontinued at the second occurrence of 
Grade 3/4 hepatic function abnormalities or mucositis, 
or other Grade 4 non-hematologic adverse events. Mid-
study, in compliance with the FDA guidance issued around 
changes in creatinine methodology and carboplatin dosing, 
a GFR cap of 125 mL/min was implemented for the Calvert 
formula so that the maximum dose of carboplatin for any 
patient was not to exceed 900 mg.
Doxorubicin and/or cyclophosphamide were delayed 
and/or reduced for ANC <1000/μL, platelet counts 
<75,000 lasting ≤3 weeks, or for febrile neutropenia; 
withdrawal from the study was required if ANC 
or platelets had not recovered within 3 weeks, and 
treatment was discontinued at the third episode of febrile 
neutropenia. Doxorubicin and/or cyclophosphamide were 
discontinued for the second occurrence of Grade 3/4 
vomiting or mucositis, Grade 4 hepatic function 
abnormalities or Grade 2/3 abnormalities persisting 
>3 weeks, or for Grade 3/4 hand-foot syndrome requiring 
greater than a 3 weeks delay.
No dose reductions of bevacizumab were allowed, and 
treatment was held if the chemotherapy component was 
delayed. Bevacizumab was held for a left ventricular 
ejection fraction (LVEF) drop ≥16% points below 
baseline or ≥6% points below lower limit of normal, 
and permanently discontinued if LVEF did not meet 
continuation criteria at the designated follow-up 
assessment. Grade 3 congestive heart failure (CHF) 
required discontinuation of bevacizumab at any cycle, 
and AC was prohibited; all study therapies were 
discontinued for Grade 4 CHF or for Grade 3/4 cardiac 
ischaemia/infarction. Bevacizumab was discontinued for 
Grade 2–4 cardiac conduction abnormalities, Grade 3/4 
supraventricular arrhythmia, or Grade 2–4 ventricular 
arrhythmia occurring during cycles 1–4; bevacizumab 
and AC were discontinued if these events occurred 
during cycles 5–8. Bevacizumab was also discontinued 
and patients withdrawn from study treatment for any 
grade arterial thrombolic events, Grade 4 proteinuria, 
Grade 4 or uncontrolled Grade 3 hypertension, 
gastrointestinal perforation, fistula, reversible posterior 
leucoencephalopathy, wound dehiscence, or any other 
Grade 4 adverse events attributable to bevacizumab. If 
bevacizumab was discontinued during the pre-operative 
phase, no post-operative bevacizumab was allowed.
Supplementary Appendix 2: RECIST Version 1.0 
Criteria for Clinical Response Assessment1
Definition of target and non-target lesions at 
baseline
during the baseline assessment, all lesions detected in the 
breast and axilla are classified as either target lesions or 
non-target lesions before the start of protocol treatment.
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Target lesions include:
• Breast tumours ≥2.0 cm on baseline physical 
examination
• Axillary nodes ≥2.0 cm on baseline physical 
examination.
Non-target lesions include:
• Breast tumours <2.0 cm on baseline physical 
examination
• Axillary nodes <2.0 cm on baseline physical 
examination.
Clinical Measurement
For the target lesion(s) in the breast and axilla, 
the longest unidimensional measurement (longest 
diameter, LD) was recorded. The clinical measurement 
for this assessment is the sum of the LD measurements 
of all target lesions.
Criteria for Evaluation of Clinical Response
• Clinical complete response
 Disappearance of all target and non-target lesions 
identified at baseline, with no evidence of disease 
progression.
• Clinical partial response
 At least a 30% decrease in the sum of the LD of target 
lesions (taking as reference the baseline sum of the 
LD). No definite progression of non-target lesions. 
No evidence of new lesions.
• Clinical stable disease
 Neither sufficient shrinkage to qualify for response 
nor sufficient increase to qualify for progressive 
disease.
• Progressive disease
 At least a 20% increase in the sum of the LD of the 
target lesions (taking as reference the smallest sum 













PR Non‑PD No PR
SD Non‑PD No SD
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
1Therasse P, Arbuck SG, Eisenhauer EA, et al. New 
guidelines to evaluate the response to treatment in 
solid tumors. European Organization for Research and 
Treatment of Cancer, National Cancer Institute of the 
United States, National Cancer Institute of Canada. J Natl 
Cancer Inst 2000;92(3):205-16.
